ATE542816T1 - Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors - Google Patents

Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors

Info

Publication number: ATE542816T1
Authority: AT; Austria
Prior art keywords: dopamine; modulators; receptor; derivatives
Prior art date: 2004-02-23

Application number

AT08169935T

Other languages

English (en)

Inventor

Luca Arista

Giorgio Bonanomi

Anna Maria Capelli

Federica Damiani

Fabio Romano Di

Gabriella Gentile

Dieter Hamprecht

Fabrizio Micheli

Luca Tarsi

Giovanna Tedesco

Silvia Terreni

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-02-23

Filing date

2005-02-21

Publication date

2012-02-15

2004-02-23 Priority claimed from GB0403990A external-priority patent/GB0403990D0/en

2004-02-24 Priority claimed from GB0404083A external-priority patent/GB0404083D0/en

2004-07-30 Priority claimed from GB0417120A external-priority patent/GB0417120D0/en

2005-02-21 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE542816T1 publication Critical patent/ATE542816T1/de

Links

102000004073 Dopamine D3 Receptors Human genes 0.000 title 1
108090000525 Dopamine D3 Receptors Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Nutrition Science (AREA)
Anesthesiology (AREA)
Otolaryngology (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT08169935T 2004-02-23 2005-02-21 Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors ATE542816T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0403990A GB0403990D0 (en)	2004-02-23	2004-02-23	Compounds
GB0404083A GB0404083D0 (en)	2004-02-24	2004-02-24	Compounds
GB0417120A GB0417120D0 (en)	2004-07-30	2004-07-30	Compounds

Publications (1)

Publication Number	Publication Date
ATE542816T1 true ATE542816T1 (de)	2012-02-15

Family

ID=34890800

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AT05707610T ATE451364T1 (de)	2004-02-23	2005-02-21	Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
AT08169935T ATE542816T1 (de)	2004-02-23	2005-02-21	Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors
AT08169934T ATE520686T1 (de)	2004-02-23	2005-02-21	Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT05707610T ATE451364T1 (de)	2004-02-23	2005-02-21	Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT08169934T ATE520686T1 (de)	2004-02-23	2005-02-21	Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors

Country Status (25)

Country	Link
US (3)	US7855298B2 (de)
EP (3)	EP2060570B1 (de)
JP (1)	JP4960217B2 (de)
KR (1)	KR101143718B1 (de)
CN (1)	CN1946714B (de)
AR (1)	AR047890A1 (de)
AT (3)	ATE451364T1 (de)
AU (2)	AU2005215918C1 (de)
BR (1)	BRPI0507945A (de)
CA (1)	CA2557115C (de)
CY (3)	CY1109854T1 (de)
DE (1)	DE602005018190D1 (de)
DK (3)	DK1745040T3 (de)
ES (2)	ES2380990T3 (de)
HR (3)	HRP20100114T1 (de)
IL (1)	IL177184A0 (de)
MA (1)	MA28438B1 (de)
NO (1)	NO20064309L (de)
PE (1)	PE20051173A1 (de)
PL (3)	PL2060570T3 (de)
PT (3)	PT1745040E (de)
RU (1)	RU2434011C2 (de)
SI (3)	SI1745040T1 (de)
TW (1)	TW200538113A (de)
WO (1)	WO2005080382A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1745040E (pt) *	2004-02-23	2010-03-08	Glaxo Group Ltd	Derivados do azabiciclo3.1.0-hexano úteis como moduladores dos receptores d3 da dopamina
US20070043100A1 (en)	2005-08-16	2007-02-22	Hagen Eric J	Novel polymorphs of azabicyclohexane
GB0507601D0 (en) *	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507602D0 (en)	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507680D0 (en)	2005-04-15	2005-05-25	Glaxo Group Ltd	Compounds
GB0512099D0 (en) *	2005-06-14	2005-07-20	Glaxo Group Ltd	Compounds
EP1891056B1 (de)	2005-06-14	2010-10-13	Glaxo Group Limited	Neue verbindungen
WO2007006117A1 (en) *	2005-07-13	2007-01-18	Nicogen Inc.	Novel cyp2a6 inhibitors
EP1915146A4 (de)	2005-07-27	2010-06-02	Dov Pharmaceutical Inc	Neuartige 1-aryl-3-azabicyclo[3.1.0]hexane. herstellung und verwendung zur behandlung von neuropsychiatrischen erkrankungen
GB0517175D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517187D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517193D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Novel use
US7799815B2 (en) *	2005-08-22	2010-09-21	Glaxo Group Limited	Triazole derivatives as modulators of dopamine D3 receptors
GB0517191D0 (en)	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
EA200870404A1 (ru)	2006-04-03	2009-04-28	Глэксо Груп Лимитед	Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3
GB0607899D0 (en) *	2006-04-03	2006-05-31	Glaxo Group Ltd	Process for preparing heterocyclic derivatives
GB0703387D0 (en) *	2007-02-21	2007-03-28	Glaxo Group Ltd	Novel compounds
WO2007113258A1 (en) *	2006-04-03	2007-10-11	Glaxo Group Limited	Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors
EP2007751B1 (de) *	2006-04-03	2013-08-21	Glaxo Group Limited	Azabicyclo[3.1.0]hexylderivate als modulatoren von dopamin-d3-rezeptoren
GB0608452D0 (en) *	2006-04-27	2006-06-07	Glaxo Group Ltd	Novel compounds
US20080045725A1 (en)	2006-04-28	2008-02-21	Murry Jerry A	Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
GB0616574D0 (en) *	2006-08-21	2006-09-27	Glaxo Group Ltd	Compounds
US8138377B2 (en)	2006-11-07	2012-03-20	Dov Pharmaceutical, Inc.	Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
EP2167083B1 (de) *	2007-06-06	2015-10-28	Euthymics Bioscience, Inc.	1- heteroaryl-3-azabicyclo[3.1.0]hexane, verfahren zu ihrer herstellung und ihre verwendung als medikamente
US9133159B2 (en)	2007-06-06	2015-09-15	Neurovance, Inc.	1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
GB0719235D0 (en)	2007-10-02	2007-11-14	Glaxo Group Ltd	Novel compounds
GB0719234D0 (en) *	2007-10-02	2007-11-14	Glaxo Group Ltd	Novel compounds
MX2010014500A (es)	2008-06-24	2011-05-30	Codexis Inc	Procedimientos biocataliticos para la preparacion de compuestos de prolina biciclica fusionada sustancialmente estereomericamente puros.
US8536185B2 (en) *	2008-09-22	2013-09-17	Cayman Chemical Company, Incorporated	Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
KR20120106697A (ko) *	2009-06-26	2012-09-26	파나세아 바이오테크 리미티드	신규 아자비시클로헥산
US20140206740A1 (en)	2011-07-30	2014-07-24	Neurovance, Inc.	Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
EP3068226A4 (de) *	2013-11-11	2017-05-17	Euthymics Bioscience, Inc.	Neuartige verfahren
ES2821896T3 (es)	2015-08-05	2021-04-28	Indivior Uk Ltd	Antagonistas del receptor de dopamina D3 que tienen una unidad estructural biciclo
US11447484B2 (en)	2018-01-26	2022-09-20	Shionogi & Co., Ltd.	Cyclic compound having dopamine D3 receptor antagonistic effect
AU2021296163B2 (en)	2020-06-22	2024-07-04	Corcept Therapeutics Incorporated	Quaternary indazole glucocorticoid receptor antagonists
US12115154B2 (en)	2020-12-16	2024-10-15	Srx Cardio, Llc	Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
IL313663A (en)	2021-12-21	2024-08-01	Corcept Therapeutics Inc	Piperazine indazole glucocorticoid receptor antagonists
KR20240125035A (ko)	2021-12-21	2024-08-19	코어셉트 쎄라퓨틱스 인코포레이티드	이환 인다졸 글루코코르티코이드 수용체 길항제

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI274750B (en) *	1999-01-12	2007-03-01	Abbott Gmbh & Co Kg	Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
GB0015562D0 (en) *	2000-06-23	2000-08-16	Pfizer Ltd	Heterocycles
EP1335915B1 (de)	2000-11-14	2008-01-02	Smithkline Beecham Plc	Tetrahydrobenzazepin-derivate zur verwendung als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel)
US6569887B2 (en) *	2001-08-24	2003-05-27	Dov Pharmaceuticals Inc.	(−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
EA006708B1 (ru) *	2001-10-22	2006-02-24	Пфайзер Продактс Инк.	Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
WO2004014881A2 (en) *	2002-08-09	2004-02-19	Astra Zeneca Ab	'1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
PT1745040E (pt) *	2004-02-23	2010-03-08	Glaxo Group Ltd	Derivados do azabiciclo3.1.0-hexano úteis como moduladores dos receptores d3 da dopamina
GB0507601D0 (en) *	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507602D0 (en)	2005-04-14	2005-05-18	Glaxo Group Ltd	Compounds
GB0507680D0 (en) *	2005-04-15	2005-05-25	Glaxo Group Ltd	Compounds
EP1891056B1 (de)	2005-06-14	2010-10-13	Glaxo Group Limited	Neue verbindungen
GB0517175D0 (en)	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
US7799815B2 (en) *	2005-08-22	2010-09-21	Glaxo Group Limited	Triazole derivatives as modulators of dopamine D3 receptors
GB0517187D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517191D0 (en)	2005-08-22	2005-09-28	Glaxo Group Ltd	Compounds
GB0517193D0 (en) *	2005-08-22	2005-09-28	Glaxo Group Ltd	Novel use
EA200870404A1 (ru)	2006-04-03	2009-04-28	Глэксо Груп Лимитед	Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3
GB0616574D0 (en) *	2006-08-21	2006-09-27	Glaxo Group Ltd	Compounds

2005
- 2005-02-21 PT PT05707610T patent/PT1745040E/pt unknown
- 2005-02-21 ES ES08169935T patent/ES2380990T3/es not_active Expired - Lifetime
- 2005-02-21 DE DE602005018190T patent/DE602005018190D1/de not_active Expired - Lifetime
- 2005-02-21 EP EP08169935A patent/EP2060570B1/de not_active Expired - Lifetime
- 2005-02-21 US US10/598,200 patent/US7855298B2/en not_active Expired - Fee Related
- 2005-02-21 DK DK05707610.1T patent/DK1745040T3/da active
- 2005-02-21 DK DK08169934.0T patent/DK2070922T3/da active
- 2005-02-21 EP EP08169934A patent/EP2070922B1/de not_active Expired - Lifetime
- 2005-02-21 SI SI200530923T patent/SI1745040T1/sl unknown
- 2005-02-21 PE PE2005000205A patent/PE20051173A1/es not_active Application Discontinuation
- 2005-02-21 AT AT05707610T patent/ATE451364T1/de active
- 2005-02-21 PL PL08169935T patent/PL2060570T3/pl unknown
- 2005-02-21 AR ARP050100632A patent/AR047890A1/es not_active Application Discontinuation
- 2005-02-21 KR KR1020067016833A patent/KR101143718B1/ko not_active Expired - Fee Related
- 2005-02-21 SI SI200531503T patent/SI2060570T1/sl unknown
- 2005-02-21 JP JP2007500152A patent/JP4960217B2/ja not_active Expired - Fee Related
- 2005-02-21 TW TW094105108A patent/TW200538113A/zh unknown
- 2005-02-21 AU AU2005215918A patent/AU2005215918C1/en not_active Ceased
- 2005-02-21 PL PL05707610T patent/PL1745040T3/pl unknown
- 2005-02-21 AT AT08169935T patent/ATE542816T1/de active
- 2005-02-21 EP EP05707610A patent/EP1745040B9/de not_active Expired - Lifetime
- 2005-02-21 CA CA2557115A patent/CA2557115C/en not_active Expired - Fee Related
- 2005-02-21 AT AT08169934T patent/ATE520686T1/de active
- 2005-02-21 DK DK08169935.7T patent/DK2060570T3/da active
- 2005-02-21 CN CN2005800126155A patent/CN1946714B/zh not_active Expired - Fee Related
- 2005-02-21 PT PT08169934T patent/PT2070922E/pt unknown
- 2005-02-21 PL PL08169934T patent/PL2070922T3/pl unknown
- 2005-02-21 SI SI200531398T patent/SI2070922T1/sl unknown
- 2005-02-21 BR BRPI0507945-4A patent/BRPI0507945A/pt active Search and Examination
- 2005-02-21 WO PCT/EP2005/001940 patent/WO2005080382A1/en not_active Ceased
- 2005-02-21 ES ES05707610T patent/ES2337590T3/es not_active Expired - Lifetime
- 2005-02-21 HR HR20100114T patent/HRP20100114T1/hr unknown
- 2005-02-21 RU RU2006133909/04A patent/RU2434011C2/ru not_active IP Right Cessation
- 2005-02-21 PT PT08169935T patent/PT2060570E/pt unknown
2006
- 2006-07-31 IL IL177184A patent/IL177184A0/en unknown
- 2006-08-22 MA MA29286A patent/MA28438B1/fr unknown
- 2006-09-22 NO NO20064309A patent/NO20064309L/no not_active Application Discontinuation
2009
- 2009-09-01 AU AU2009212887A patent/AU2009212887A1/en not_active Abandoned
- 2009-12-16 US US12/639,282 patent/US8283474B2/en not_active Expired - Fee Related
- 2009-12-16 US US12/639,129 patent/US8263782B2/en not_active Expired - Fee Related
2010
- 2010-03-01 CY CY20101100197T patent/CY1109854T1/el unknown
2011
- 2011-10-26 HR HR20110781T patent/HRP20110781T1/hr unknown
- 2011-11-07 CY CY20111101073T patent/CY1112011T1/el unknown
2012
- 2012-03-29 HR HR20120281T patent/HRP20120281T1/hr unknown
- 2012-04-11 CY CY20121100356T patent/CY1113029T1/el unknown

Also Published As

Publication number	Publication date
AU2005215918C1 (en)	2010-01-21
RU2434011C2 (ru)	2011-11-20
SI1745040T1 (sl)	2010-04-30
PL2060570T3 (pl)	2012-06-29
EP1745040B9 (de)	2010-06-02
TW200538113A (en)	2005-12-01
ES2380990T3 (es)	2012-05-22
CA2557115A1 (en)	2005-09-01
KR101143718B1 (ko)	2012-07-05
IL177184A0 (en)	2006-12-10
US20100160336A1 (en)	2010-06-24
PL2070922T3 (pl)	2012-01-31
BRPI0507945A (pt)	2007-07-24
HRP20100114T1 (hr)	2010-04-30
CN1946714A (zh)	2007-04-11
AU2005215918A1 (en)	2005-09-01
KR20060127991A (ko)	2006-12-13
CY1113029T1 (el)	2016-04-13
DK2070922T3 (da)	2011-11-28
US7855298B2 (en)	2010-12-21
EP1745040A1 (de)	2007-01-24
HRP20120281T1 (hr)	2012-04-30
SI2060570T1 (sl)	2012-05-31
PT2070922E (pt)	2011-11-24
EP2060570A3 (de)	2009-06-03
ATE520686T1 (de)	2011-09-15
RU2006133909A (ru)	2008-03-27
ES2337590T3 (es)	2010-04-27
US20070142438A1 (en)	2007-06-21
MA28438B1 (fr)	2007-02-01
CN1946714B (zh)	2011-06-15
CA2557115C (en)	2012-10-02
CY1109854T1 (el)	2014-09-10
CY1112011T1 (el)	2015-11-04
US8263782B2 (en)	2012-09-11
JP2007523208A (ja)	2007-08-16
WO2005080382A1 (en)	2005-09-01
AR047890A1 (es)	2006-03-01
EP2060570B1 (de)	2012-01-25
EP2070922B1 (de)	2011-08-17
EP1745040B1 (de)	2009-12-09
JP4960217B2 (ja)	2012-06-27
PT2060570E (pt)	2012-05-07
DK2060570T3 (da)	2012-04-30
US8283474B2 (en)	2012-10-09
DE602005018190D1 (de)	2010-01-21
US20100152195A1 (en)	2010-06-17
HK1103016A1 (en)	2007-12-14
EP2060570A2 (de)	2009-05-20
HRP20110781T1 (hr)	2011-11-30
NO20064309L (no)	2006-11-23
AU2009212887A1 (en)	2009-09-24
AU2005215918B2 (en)	2009-06-11
PE20051173A1 (es)	2006-02-14
EP2070922A1 (de)	2009-06-17
PL1745040T3 (pl)	2010-05-31
SI2070922T1 (sl)	2011-12-30
PT1745040E (pt)	2010-03-08
DK1745040T3 (da)	2010-04-12
ATE451364T1 (de)	2009-12-15

Publication	Publication Date	Title
ATE520686T1 (de)	2011-09-15	Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors
DE122012000018I1 (de)	2012-06-06	Benzimidazolderivate und ihre verwendung als antagonisten des a II rezeptors.
ATE543808T1 (de)	2012-02-15	5,6-ring-annelierte indolderivate und ihre verwendung
DE602005027307D1 (de)	2011-05-19	Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
ATE520681T1 (de)	2011-09-15	N-thioanthranilamidverbindungen und ihre verwendung als pestizide
ATE497953T1 (de)	2011-02-15	Thiazolderivate als modulatoren des cannabinoidrezeptors
ATE450517T1 (de)	2009-12-15	Isoxazolinderivate und ihre verwendung als herbizide
ATE473214T1 (de)	2010-07-15	2-(4-oxo-4h-chinazolin-3-yl)acetamide und ihre verwendung als vasopressin-v3-antagonisten
ATE440093T1 (de)	2009-09-15	1-alkinyl-2-aryloxyalkylamide und ihre verwendung als fungizide
ATE432975T1 (de)	2009-06-15	Flüssigwaschmittel und ihre verwendung
ATE454377T1 (de)	2010-01-15	2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor
ATE400571T1 (de)	2008-07-15	Pyrrolyl-thiazole und ihre verwendung als inverse agonisten des cb 1 rezeptors
DE602007008572D1 (de)	2010-09-30	Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten
ATE428710T1 (de)	2009-05-15	Substituierte phenylaminothiazole und ihre verwendung
DE602004010426D1 (de)	2008-01-10	Mikrobizide zusammensetzungen und ihre verwendung
ATE432701T1 (de)	2009-06-15	Indol-6-sulfonamid-derivate, ihre herstellung und ihre verwendung als 5-ht-6 modulatoren
ATE518834T1 (de)	2011-08-15	2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
DE60320457D1 (de)	2008-05-29	Tetrahydrochinolinderivate und deren verwendung als modulatoren des fsh rezeptors
DE602004014772D1 (de)	2008-08-14	Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
DE602004021384D1 (de)	2009-07-16	Indol-5 -sulfonamid-derivate, ihre herstellung und verwendung als 5-ht-6 modulatoren
DE602006009804D1 (de)	2009-11-26	Piperidin-4-yl-amidderivate und ihre verwendung als antagonisten des sst-rezeptors vom subtyp 5
ATE513817T1 (de)	2011-07-15	Pyrimidinderivate und ihre verwendung als pestizide
ATE486070T1 (de)	2010-11-15	Piperidinylaminopyridazine und ihre verwendung als schnelldissoziierende antagonisten des dopamin-2-rezeptors
ATE442366T1 (de)	2009-09-15	Oxazolidinonderivate und ihre verwendung als antibiotika
DE602006009296D1 (de)	2009-10-29	Oligopeptide und ihre verwendung